(Q35930659)

11 August 2017

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial (English)

1 reference

11 August 2017

0 references

1 reference

11

Herve Avet-Loiseau

0 references

Cyrille Hulin

8

object named as

Cyrille Hulin

0 references

Thierry Facon

18

object named as

Thierry Facon

1 reference

11 August 2017

4

Tadeusz Robak

1 reference

11 August 2017

Martin Kropff

1

1 reference

11 August 2017

Honorata Giongco Baylon

2

1 reference

11 August 2017

Jens Hillengass

3

1 reference

11 August 2017

Roman Hajek

5

1 reference

11 August 2017

Peter Liebisch

6

1 reference

11 August 2017

Stefan Goranov

7

1 reference

11 August 2017

Joan Bladé

9

1 reference

11 August 2017

Tommaso Caravita

10

1 reference

11 August 2017

Thomas M Moehler

12

1 reference

11 August 2017

Claire Pattou

13

1 reference

11 August 2017

Lela Lucy

14

1 reference

11 August 2017

Elisabeth Kueenburg

15

1 reference

11 August 2017

Axel Glasmacher

16

1 reference

11 August 2017

Robert Zerbib

17

1 reference

11 August 2017

1 December 2011

1 reference

11 August 2017

1 reference

11 August 2017

97

1 reference

11 August 2017

5

1 reference

11 August 2017

784-791

1 reference

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Improved survival in multiple myeloma and the impact of novel therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Relapsed multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Antitumor activity of thalidomide in refractory multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Primary dexamethasone treatment of multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Clinical course of patients with relapsed multiple myeloma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342984

High-dose glucocorticoid treatment of resistant myeloma

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22133776

12 December 2020

inferred from PubMed ID database lookup

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22133776

12 December 2020

inferred from PubMed ID database lookup

An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22133776

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.3324/HAEMATOL.2011.044271

1 reference

release_ljkdvqca3fcdvleyxdwa7yxkhm

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ljkdvqca3fcdvleyxdwa7yxkhm

24 November 2022

mapped directly with Wikidata item

1 reference

11 August 2017

PubMed publication ID

22133776

1 reference